No Effect of Clopidogrel Activity or Cessation on Vascular Function or Markers of Inflammation

Abstract

The platelet adenosine diphosphate (ADP)-receptor blocker clopidogrel is effective in reducing the rate of thrombosis in cardiovascular disease, but may also have nonplatelet activity. However, there is variability in the suppression of platelet function in individuals, leading to the concept of clopidogrel resistance, that is, reduced platelet-suppressing activity. We tested the hypothesis that some of the beneficial effect of clopidogrel may be due to the variable activity of this drug on the vascular system (assessed by plasma markers von Willebrand factor and soluble E-selectin, and functional arterial pulse wave velocity) and inflammation (C-reactive protein and interleukin-6) while 32 patients with coronary artery disease taking 75 mg clopidogrel daily, and again 2 weeks after cessation of clopidogrel therapy. Platelet responsiveness to clopidogrel was assessed by the phosphorylation of intracellular regulatory protein—vasodilator-stimulated phosphoprotein method and aggregometry to ADP. Response to aspirin was assessed using arachidonic acid (AA), and soluble P-selectin and PAC-1 were also measured. While on clopidogrel, there were no relationships between any vascular or inflammatory index and the response to clopidogrel. After stopping clopidogrel, there were no differences in platelet aggregation to AA, or the expression of P-selectin or PAC-1 at rest, or after stimulation by AA, but platelet responses to ADP all increased (p < 0.01). Although soluble P-selectin increased when clopidogrel was stopped (p = 0.006), there were no changes in plasma markers or vascular function. We conclude that 75 mg/day clopidogrel has no effect of markers of vascular function or inflammation.

Keywords

clopidogrel - platelet aggregation - vascular function - inflammation - coronary artery disease - platelet aggregation

• References

• 1 Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007; 18 (3) CD005158
• 2 Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 2011; 128 (4) 307-316
• 3 American College of Cardiology; American Heart Association Task Force on Practice Guidelines. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheter Cardiovasc Interv 2008; 71 (1) E1-E40
• 4 Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45 (8) 1157-1164
• 5 Mallouk N, Labruyère C, Reny JL , et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost 2012; 107 (3) 494-506
• 6 Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag 2010; 6: 109-112
• 7 França CN, Pinheiro LF, Izar MC , et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 2012; 76 (3) 729-736
• 8 Holowatz LA, Jennings JD, Lang JA, Kenney WL. Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans. J Appl Physiol 2010; 108 (6) 1575-1581
• 9 Heitzer T, Rudolph V, Schwedhelm E , et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26 (7) 1648-1652
• 10 Warnholtz A, Ostad MA, Velich N , et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008; 196 (2) 689-695
• 11 Lecka J, Rana MS, Sévigny J. Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation. Br J Pharmacol 2010; 161 (5) 1150-1160
• 12 Waehre T, Damås JK, Pedersen TM , et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006; 4 (10) 2140-2147
• 13 Wykrzykowska JJ, Warnholtz A, de Jaeger P , et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 2009; 28 (4) 410-417
• 14 Schäfer A, Weinberger S, Flierl U , et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008; 100 (4) 618-625
• 15 Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005; 94 (4) 886-887
• 16 Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010; 56 (5) 839-847
• 17 Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50 (19) 1822-1834
• 18 Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 2007; 49 (19) 1957-1964
• 19 Schmitz G, Rothe G, Ruf A , et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79 (5) 885-896
• 20 Shantsila E, Wrigley B, Shantsila A , et al. Ethnic differences in macrovascular and microvascular function in systolic heart failure. Circ Heart Fail 2011; 4 (6) 754-762
• 21 Machin D, Campbell M. Statistical Tables for the Design of Clinical Trials. Oxford: Blackwell Scientific; 1987
• 22 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14 (1) 55-61
• 23 Djukanovic N, Todorovic Z, Obradovic S , et al. Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events. J Pharmacol Sci 2011; 117 (1) 12-18
• 24 Michelson AD, Barnard MR, Hechtman HB , et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996; 93 (21) 11877-11882
• 25 Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24 (24) 2166-2179
• 26 Lim HS, Lip GY. Arterial stiffness: beyond pulse wave velocity and its measurement. J Hum Hypertens 2008; 22 (10) 656-658